NCT05599984
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors
- NCT05599984 ↗
- Active not recruiting
- AbbVie
- 5 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 5 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combination With Budigalimab (ABBV-181), Carboplatin, or Cisplatin in Adult Subjects With Advanced Solid Tumors
- Phase
- Phase 1
- Status
- Active not recruiting
- Conditions
- Advanced Solid Tumors
- Interventions
- ABBV-706; Cisplatin; Budigalimab; Carboplatin
- Arms
- Part 1: ABBV-706 Monotherapy Dose Escalation · Experimental
- Part 2: ABBV-706 Monotherapy Dose Optimization and Expansion · Experimental
- Part 3a: ABBV-706 + Budigalimab · Experimental
- Part 3b: ABBV-706 + Platinum Chemotherapy · Experimental
- Part 4a: ABBV-706 Monotherapy Dose Expansion CNS Tumors · Experimental
- Part 4b: ABBV-706 Monotherapy Dose Expansion NECs · Experimental
- Enrollment
- 288
- Primary outcomes
- Percentage of Participants With Adverse Events (AE)
- Maximum Observed Serum/Plasma Concentration (Cmax) of ABBV-706
- Time to Cmax (Tmax) of ABBV-706
- Terminal Phase Elimination Half-Life (t1/2) of ABBV-706
- Area Under the Serum/Plasma Concentration-Time Curve (AUC) of ABBV-706
- Antidrug Antibodies (ADAs)
- Neutralizing Antibodies (nAbs)
- Percentage of Participants with Objective Response, for Participants with Extracranial Solid Tumors
- Recommended Phase 2 Dose (RP2D) of ABBV-706
- Percentage of Participants with Objective Response for Participants with Central Nervous System (CNS) Tumors
- Duration of response (DOR) for Participants with Confirmed CR/PR
- Percentage of Participants with Clinical Benefit
- Progression-Free Survival (PFS)
- Overall survival (OS)
- Sponsor
- AbbVie
- Start
- Dec 5, 2022
- Primary completion
- Nov 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05599984 · updated May 7, 2026
Publications
linked from the registry- Byers LA, Cho BC, Cooper AJ, Chiang AC, Han JY, Furqan M, Dowlati A, Morgensztern D, Papadopoulos KP, Choudhury NJ, Vieito M, Bar J, Kim JH, Akerley W, Kim TM, Kim YC, Paz-Ares L, Ahn MJ, Yokouchi H, Meiman D, Munasinghe W, Ogunyankin O, Jahchan N, Wang S, Ferlini C, Robinson RR, Kohlhapp FJ, Palenski T, Rivell G, Hingorani P, Chandana S. SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial. Nat Med. 2026 Aug;32(8):2898-2908. doi: 10.1038/s41591-026-04452-0. Epub 2026 Jun 1. PubMed 42225988